Ataprost | CAS#83997-19-7 | inhibits platelet aggregation.

MedKoo Cat#: 593007 | Name: Ataprost

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ataprost, also known as ONO 41483 and OP 41483 is a potent inhibitor of platelet aggregation. ONO 41483 was 3.3 times less active than prostacyclin but was 2.6 times more active than carboprostacyclin in inhibiting aggregation of ADP-induced baboon platelet in vitro. Intravenous and oral administration of ONO 41483 in baboons produced ex vivo inhibition of ADP-induced platelet aggregation at doses that did not affect blood pressure or heart rate.

Chemical Structure

Ataprost

CAS#83997-19-7

Theoretical Analysis

MedKoo Cat#: 593007

Name: Ataprost

CAS#: 83997-19-7

Chemical Formula: C21H32O4

Exact Mass: 348.2301

Molecular Weight: 348.48

Elemental Analysis: C, 72.38; H, 9.26; O, 18.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ataprost; ONO 41483; ONO41483; ONO-41483; OP 41483; OP-41483; OP41483; tepoprostenol;

IUPAC/Chemical Name

Pentanoic acid, 5-(4-(3-cyclopentyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2(1H)-pentalenylidene)-, (3aS-(2E,3aalpha,4alpha(1E,3R*),5beta,6aalpha))-

InChi Key

DKLGLHQHLFISGJ-ZXLAMGRHSA-N

InChi Code

InChI=1S/C21H32O4/c22-19(15-6-2-3-7-15)10-9-17-18-12-14(5-1-4-8-21(24)25)11-16(18)13-20(17)23/h5,9-10,15-20,22-23H,1-4,6-8,11-13H2,(H,24,25)/b10-9+,14-5-/t16-,17+,18-,19+,20+/m0/s1

SMILES Code

OC(CCC/C=C(C1)/C[C@@H]2[C@H]1[C@@H](/C=C/[C@@H](O)C3CCCC3)[C@H](O)C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 348.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Takahama T, Kanai F, Onishi K. Anticoagulation during use of a left ventricular assist device. ASAIO J. 2000 May-Jun;46(3):354-7. PubMed PMID: 10826751. 2: Ejiri S, Eguchi Y, Kishida A, Kurumi Y, Tani T, Kodama M. Protective effect of OPC-6535, a superoxide anion production inhibitor, on liver grafts subjected to warm ischemia during porcine liver transplantation. Transplant Proc. 2000 Mar;32(2):318-21. PubMed PMID: 10715428. 3: Totsuka E, Todo S, Zhu Y, Ishizaki N, Kawashima Y, Jin MB, Urakami A, Shimamura T, Starzl TE. Attenuation of ischemic liver injury by prostaglandin E1 analogue, misoprostol, and prostaglandin I2 analogue, OP-41483. J Am Coll Surg. 1998 Sep;187(3):276-86. PubMed PMID: 9740185; PubMed Central PMCID: PMC3022419. 4: Zushi S, Shinomura Y, Kiyohara T, Minami T, Sugimachi M, Higashimoto Y, Kanayama S, Matsuzawa Y. Role of prostaglandins in intestinal epithelial restitution stimulated by growth factors. Am J Physiol. 1996 May;270(5 Pt 1):G757-62. PubMed PMID: 8967486. 5: Ejiri S, Eguchi Y, Kishida A, Xie G, Kurumi Y, Kodama M. Protective effect of a prostaglandin I2 analogue on grafted livers subjected to in situ warm ischemia in porcine orthotopic liver transplantation: immunohistochemical analysis of thrombomodulin. Transplant Proc. 1996 Apr;28(2):1086-8. PubMed PMID: 8623235. 6: Takahama T, Kanai F, Onishi K, Yamazaki Z, Furuse A, Yoshitake T. Ideal anticoagulation for use with a left ventricular assist device. ASAIO J. 1995 Jul-Sep;41(3):M779-82. PubMed PMID: 8573913. 7: Nakano H, Monden M, Umeshita K, Murata M, Miyoshi H, Kanai T, Gotoh M, Mori T. Cytoprotective effect of prostaglandin I2 analogues on superoxide-induced hepatocyte injury. Surgery. 1994 Nov;116(5):883-9. PubMed PMID: 7940193. 8: Umeki S. Prostaglandin E and analogs of prostacyclin influencing superoxide production by the human neutrophil NADPH oxidase system. Int J Biochem. 1994 Aug;26(8):1003-8. PubMed PMID: 8088410. 9: Goto S, Kim YI, Kodama Y, Kai T, Kawano K, Delriviere L, Lynch SV, Kamada N, Kobayashi M. The effect of a prostaglandin I2 analogue (OP-41483) on energy metabolism in liver preservation and its relation to lipid peroxidative reperfusion injury in rats. Cryobiology. 1993 Oct;30(5):459-65. PubMed PMID: 8252913. 10: Uematsu T, Umemura K, Nakano M, Kosuge K, Nakashima M. Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5. PubMed PMID: 8225681. 11: Nishiyama R, Nakamura S, Suzuki S, Baba S. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue. Transplantation. 1993 Jun;55(6):1261-5. PubMed PMID: 8516812. 12: Hirafuji M, Shinoda H. Roles of prostacyclin, EDRF and active oxygens in leukocyte-dependent platelet adhesion to endothelial cells induced by platelet-activating factor in vitro. Br J Pharmacol. 1993 Jun;109(2):524-9. PubMed PMID: 8358552; PubMed Central PMCID: PMC2175688. 13: Abe T, Lynch S, Balderson G, Pillay P, Akiyama T, Inuzuka S, Matsunami H, Strong R. The effects of prostacyclin analog OP-41483 on normothermic liver ischemia and reperfusion injury in rats. Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):417-22. PubMed PMID: 8341718. 14: Saito T. The protective effect of prostaglandin I2 analog (OP-41483) on hemodynamics and oxygen metabolism in normothermic liver ischemia. Fukushima J Med Sci. 1993 Jun;39(1):43-62. PubMed PMID: 8125429. 15: Matsuo R. [Experimental study on protective effect of prostaglandin I2 derivative (OP-41483) on damage of warm ischemic kidney]. Nihon Hinyokika Gakkai Zasshi. 1993 May;84(5):857-65. Japanese. PubMed PMID: 8320891. 16: Fukunaga Y, Mine Y, Yoshikawa S, Takeuchi T, Hata F, Yagasaki O. Role of prostacyclin in acetylcholine release from myenteric plexus of guinea-pig ileum. Eur J Pharmacol. 1993 Mar 23;233(2-3):237-42. PubMed PMID: 8467869. 17: Ishibashi Y. [Experimental study of the effectiveness of ECMO (extracorporeal membrane oxygenation) and PGI2 derivative against severe respiratory failure]. Hokkaido Igaku Zasshi. 1993 Jan;68(1):65-77. Japanese. PubMed PMID: 8444405. 18: Katayama Y, Kashiwagi F, Memezawa H, Terashi A. Effect of a prostacyclin derivative (OP-41483) and a hyperosmotic agent (glycerol) on brain edema and metabolism in cerebral ischemia. Jpn Circ J. 1992 Dec;56(12):1239-47. PubMed PMID: 1479649. 19: Takeuchi K. [Reperfusion injury after heart-lung transplantation--OP41483-alpha-CD (prostaglandin I2 analogue) as a preventive for the reperfusion injury, especially the oxygen derived free radicals]. Nihon Kyobu Geka Gakkai Zasshi. 1992 Feb;40(2):225-34. Japanese. PubMed PMID: 1593162. 20: Goto S, Kim YI, Kawano K, Kai T, Kobayashi M. Efficacy of PGI2 analog in preventing ischemia reperfusion damage of liver grafts from living donors. Transpl Int. 1992;5 Suppl 1:S366-9. PubMed PMID: 14621823.